-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
A critically ill patient, who was a heroin user, was admitted to a hospital in Scotland in December 2009 and was found to be infected with Bacillus anthracis.
-
The purpose of this study was to estimate the association between antibacterial medications and selected birth defects. The authors conducted a population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs.
-
-
A retrospective cohort study was conducted of all children age birth to five years enrolled at a Department of Defense treatment facility between January 1998 and December 2005, who were diagnosed with bacterial enteritis.
-
-
Morbidities and mortalities among adolescents often are the result of risk-taking behaviors. By tracking behavioral trends, clinicians can provide more tailored education, counseling, and screenings to adolescents.
-
American women might have another option in emergency contraception (EC) if the Food and Drug Administration (FDA) follows the recommendation of its reproductive health panel in approving ulipristal acetate (UPA).
-
Adaora Adimora, MD, MPH, professor of medicine in the Division of Infectious Disease at the University of North Carolina School of Medicine in Chapel Hill, recently discussed her research on the nuances of HIV risk behavior among women with AHC Media, publisher of Contraceptive Technology Update.
-
Check for use of erectile dysfunction (ED) drugs among older male patients; a new analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases (STDs) than were non-users.